Consensus Guidelines on Improving the Management of HAE
The US HAEA is committed to seeing patients lead a full and healthy life through research and education. The primary objective of this educational activity is to affect practice change by providing practical, evidence-based guidelines on the management of patients with HAE due to C1 Inhibitor deficiency.
The treatment of hereditary angioedema (HAE) has undergone dramatic changes as newer medicines have become available in recent years. Optimal care of these patients requires a comprehensive management plan that is specific to the patient. Although several consensus papers have been published concerning the diagnosis and treatment of HAE, the US HAEA's 2013 Recommendations for the Management of Hereditary Angioedema Due to C1 Inhibitor Deficiency are the first set of guidelines for a comprehensive management plan of HAE. Members of the US Hereditary Angioedema Association Medical Advisory Board began by reviewing the literature concerning treatment of HAE. Preliminary recommendations were developed based on the extensive literature review, discussions in a face-to-face meeting, and refinements in a series of distributed drafts. Final recommendations reflect the unanimous consensus of the Medical Advisory Board and the US Hereditary Angioedema Association leadership.
This accredited educational activity reviews and discusses the implementation of the consensus guidelines in order to create a successful patient centric management plan.